triumph trial retatrutide Breaking: New data just released. TRIUMPH-1 study results on the triple agonist. Eli Lilly's clinical trial on Retatrutide (triple agonist compound). 80 weeks. Phase 3 data. The results: At 12mg Retatrutide's Triumph: Lilly's Triple Agonist

The proposed mechanism involves improved blood flow to exercising muscle through enhanced nitric oxide production, reduced oxidative damage via antioxidant effects, and more efficient substrate utilization during recovery [3]

References Gibellini L, Pinti M, Nasi M, et al

Knapen MF et al

Since they're often discussed as 'supplements' in the wellness community, it's super important to do your homework

[PMID: 38952487] PubMed record related to this compound for laboratory literature review

Third, significant variations in the duration of follow-up of the included studies may have impacted the findings related to colorectal cancer risk